Analysts expect Gamida Cell Ltd (NASDAQ:GMDA) to post earnings of ($0.55) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Gamida Cell’s earnings. The firm is expected to announce its next quarterly earnings report before the market opens on Tuesday, August 6th.

On average, analysts expect that Gamida Cell will report full-year earnings of ($1.95) per share for the current financial year. For the next fiscal year, analysts forecast that the business will post earnings of ($1.50) per share. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Gamida Cell.

Gamida Cell (NASDAQ:GMDA) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.25).

Several research analysts have commented on the company. ValuEngine downgraded Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Zacks Investment Research downgraded GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a report on Thursday, July 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. Gamida Cell currently has an average rating of “Buy” and an average price target of $18.67.

NASDAQ GMDA traded up $0.17 during trading on Monday, hitting $3.94. The company’s stock had a trading volume of 17,600 shares, compared to its average volume of 22,590. The company has a current ratio of 6.52, a quick ratio of 6.52 and a debt-to-equity ratio of 0.36. The business’s 50 day moving average is $5.65. The firm has a market cap of $91.32 million and a price-to-earnings ratio of -0.37. Gamida Cell has a 52 week low of $3.71 and a 52 week high of $15.41.

Several institutional investors have recently made changes to their positions in the business. Edmond DE Rothschild Holding S.A. acquired a new position in Gamida Cell during the 1st quarter valued at approximately $53,000. Norges Bank acquired a new position in Gamida Cell during the 4th quarter valued at approximately $88,000. Millennium Management LLC purchased a new stake in shares of Gamida Cell during the 4th quarter worth approximately $210,000. Finally, FMR LLC purchased a new stake in shares of Gamida Cell during the 4th quarter worth approximately $1,243,000. Institutional investors own 1.72% of the company’s stock.

Gamida Cell Company Profile

Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

Featured Story: Preferred Stock

Get a free copy of the Zacks research report on Gamida Cell (GMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gamida Cell (NASDAQ:GMDA)

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.